Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

20.09 -0.14 (-0.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bicycle Therapeutics Plc ADR

< Previous 1 2 3 Next >
Where Bicycle Therapeutics Stands With Analysts
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million. 
Via Benzinga
Why Bicycle Therapeutics Stock Is Soaring Today
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Will Bicycle Therapeutics, With A 25% Gain Today, Take On Pfizer In Covid?
Early-stage testing shows promise for this biotech company's Covid antiviral. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume... 
Via Benzinga
Bicycle Therapeutics's Return On Capital Employed Overview
Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $3.77 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.88%, resulting in a... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Bicycle Therapeutics
Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Bicycle Therapeutics: Q4 Earnings Insights
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
Via Benzinga
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength
The list features stocks from diverse sectors as the economy recovers from the pandemic. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ: 
Via Benzinga
7 A-Rated Biotechs to Buy for the Long Run
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples. 
Via InvestorPlace
Looking Into Bicycle Therapeutics's Return On Capital Employed
According to Benzinga Pro data, during Q3, Bicycle Therapeutics (NASDAQ:BCYC) posted sales of $4.33 million. Earnings were up 17.27%, but Bicycle Therapeutics still reported an... 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
45 Biggest Movers From Yesterday
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial... 
Via Benzinga
Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a... 
Via Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Exposures Product Safety
Bicycle Therapeutics Earnings Perspective: Return On Capital Employed
Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $1.78 million during Q2 according to data provided by Benzinga Pro.However, earnings decreased 7.82%, resulting in a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.